8 Medicare Changes Every Enrollee Should Know About in 2026

Medicare changes for 2026 include higher costs for many beneficiaries — the standard Part B premium rises to $202.90/month (about +10% vs. 2025), Part D deductible increases to $615 (+4%) and the out-of-pocket Part D cap to $2,100 (+5%). Policy shifts include a six‑year pilot to require prior authorizations in original Medicare in six states using AI, reductions in some Medicare Advantage benefits (e.g., cosmetic procedures, cannabis), automatic reenrollment in the Medicare Prescription Payment Plan, an annual $35 cap on one‑month insulin supplies with no deductible, and targeted prescription cost reductions (notably some GLP-1 weight‑loss drugs) and continued coverage of CDC‑recommended adult vaccines.

Analysis

Market structure: Payers and utilization-management vendors gain incremental pricing power as CMS pilots prior authorization in Original Medicare and MA trims elective benefits. Winners include large vertically integrated payers (UNH, CVS) and health-IT/AI vendors that embed prior-auth engines; losers are high-cost specialty drug makers (LLY, NVO) and providers that depend on elective/cosmetic revenue. Expect negotiated unit-price pressure of 10–30% on targeted drug categories over 12–24 months if CMS scales protocols.

Risk assessment: Tail risks include a CMS flip from pilot to broad mandatory prior auth (high-impact, 12–36 months) or legal/regulatory pushback on AI-driven denials leading to reputational/financial hit for vendors. Near-term (0–3 months) volatility centers on enrollment and formulary updates; medium-term (3–12 months) risk is GLP‑1 pricing/negotiation revelations; long-term (1–3 years) is structural shift in payer/provider margins. Hidden dependency: commercial payers often follow Medicare pricing — CMS actions can cascade into commercial contracting and biosimilar adoption.

Trade implications: Direct play: overweight UNH (2–3% portfolio) for Optum's advantage in prior-auth and PBM scale; use 6–12 month call spreads to cap capital and capture 8–15% upside. Short selective specialty pharma exposure (LLY/NVO) via 9–15 month put spreads sized 0.5–1% to hedge pricing risk if GLP‑1/weight‑loss ASPs decline 15–30%. Pair trade: long UNH, short LLY (2:1 dollar-weighted) to express payer upside vs manufacturer margin squeeze; reassess after CMS pilot results (expected 6–12 months).

Contrarian angles: Consensus underestimates enrollment stickiness in Medicare Advantage — benefit cuts could raise premiums but not trigger mass exits, limiting immediate provider volume loss. Conversely, if MA benefit cuts push beneficiaries back to Original Medicare plus Medigap, provider volumes could rise and create a re-rating opportunity for hospitals (HCA) and device makers (MDT) within 12–24 months. Hedge trades should therefore keep room for a reversal: small tactical longs in select hospital/device names (1% positions) as asymmetric hedges.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth Group (UNH) within the next 2–4 weeks; hedge with a 6–12 month call spread (buy 10% ITM, sell 25% OTM) to target ~8–15% upside and limit capital, stop-loss at -8%.
• Initiate a 0.5–1% position short via 9–15 month put spreads on Eli Lilly (LLY) and/or Novo Nordisk (NVO) (buy 10–15% OTM puts, sell 25–30% OTM) to capture downside if Medicare negotiation/price pressure reduces GLP‑1 ASPs by 15–30% over 12–24 months.
• Implement a pair trade: long UNH (2% portfolio) and short LLY (1% portfolio) dollar-weighted to express payer capture vs manufacturer margin erosion; review after CMS publishes pilot metrics (target review at 6 months).
• Allocate 0.5–1% to tactical long exposure in hospitals/devices (e.g., HCA, MDT) as a hedge against an upside reversal if MA enrollment shifts back to Original Medicare; scale in over 1–3 quarters if CMS prior-auth rollouts materially reduce MA enrollment.